Equities analysts expect Selecta Biosciences Inc (NASDAQ:SELB) to post earnings per share of ($0.29) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Selecta Biosciences’ earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.32). Selecta Biosciences posted earnings of ($0.65) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 55.4%. The firm is expected to report its next quarterly earnings results on Friday, March 20th.
According to Zacks, analysts expect that Selecta Biosciences will report full year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.26) to ($1.19). For the next year, analysts expect that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.94) to ($0.65). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Selecta Biosciences.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02.
Shares of NASDAQ SELB opened at $1.54 on Friday. The stock has a market capitalization of $74.71 million, a price-to-earnings ratio of -0.53 and a beta of 1.17. The firm’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.78. Selecta Biosciences has a 12 month low of $1.28 and a 12 month high of $6.18.
Large investors have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new stake in Selecta Biosciences in the 2nd quarter valued at $31,000. A.R.T. Advisors LLC purchased a new stake in Selecta Biosciences in the 2nd quarter worth $40,000. Morgan Stanley increased its holdings in Selecta Biosciences by 582.4% in the 2nd quarter. Morgan Stanley now owns 63,784 shares of the company’s stock worth $114,000 after acquiring an additional 54,437 shares in the last quarter. Jane Street Group LLC acquired a new position in Selecta Biosciences during the second quarter worth $195,000. Finally, Paloma Partners Management Co acquired a new position in Selecta Biosciences during the second quarter worth $275,000. Hedge funds and other institutional investors own 38.42% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Further Reading: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.